Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

Moxalactam: Clinical Summary of Efficacy and Safety

Robert B. Kammer
Reviews of Infectious Diseases
Vol. 4, Supplement. Moxalactam International Symposium (Nov. - Dec., 1982), pp. S712-S719
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4452963
Page Count: 8
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
Moxalactam: Clinical Summary of Efficacy and Safety
Preview not available

Abstract

The efficacy and safety of moxalactam disodium were studied by 173 investigators in the United States. Of 3,558 adult and pediatric patients who were treated for various infections, 2,234 met all protocol requirements for evaluation of efficacy of treatment. Effectiveness of moxalactam therapy was defined by a satisfactory bacteriologic response. The pooled data revealed that satisfactory responses were obtained in 80% of urinary tract infections, 91% of intraabdominal infections, 91% of obstetric and gynecologic infections, 92% of lower respiratory tract infections, 92% of skin and skin-structure infections, 90% of bone and joint infections, and 94% of bacteremic infections. The overall rate of efficacy of moxalactam therapy was 89%. The incidence of adverse reactions was low. Hypersensitivity occurred in 2.9% of the 3,558 patients, and gastrointestinal adverse effects, in 2.1%. No renal or hepatic toxicity was related to moxalactam therapy. Hypoprothrombinemia occurred in 25 patients, with clinically apparent bleeding in three. Alcohol intolerance was observed in four patients.

Page Thumbnails

  • Thumbnail: Page 
S712
    S712
  • Thumbnail: Page 
S713
    S713
  • Thumbnail: Page 
S714
    S714
  • Thumbnail: Page 
S715
    S715
  • Thumbnail: Page 
S716
    S716
  • Thumbnail: Page 
S717
    S717
  • Thumbnail: Page 
S718
    S718
  • Thumbnail: Page 
S719
    S719